Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2

Cancer Gene Therapy

Volumn 14, Issue 2, 2007, Pages 158-164

  Yi, T ^a,b   Wei, Y Q ^a   Tian, L ^a   Zhao, X ^b   Li, J ^a   Deng, H X ^a   Wen, Y J ^a   Zou, C H ^a   Tan, G H ^a   Kan, B ^a   Su, J M ^a   Jiang, Y ^a   Mao, Y Q ^a   Chen, P ^a   Wang, Y S ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Autoantibodies; Autoimmunity; Cytotoxicity; Matrix metalloproteinases 2

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; GELATINASE A; TUMOR CELL VACCINE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKEN; COLON ADENOCARCINOMA; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFECT; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SURVIVAL TIME; T CELL DEPLETION; TUMOR CELL;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; BASE SEQUENCE; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE, TUMOR; CHICKENS; COLONIC NEOPLASMS; DNA PRIMERS; DNA, COMPLEMENTARY; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; VACCINES, DNA;

MUS;

EID: 33846254037     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700994     Document Type: Article

References (32)

1. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-1095.
2. Parks WC, Mecham RP. Matrix Metalloproteinases. Academic Press Inc.: San Diego, CA, 1998, pp 85-113.
3. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999; 284: 1667-1670.
4. Albini A, Melchiori A, Santi L, Liotta L, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775-779.
5. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis - an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
6. Ahmad A, Hanby A, Dublin E, Poulsom R, Smith P, Barnes D et al. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma expression. Am J Path 1998; 152: 721-728.
7. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Cur Opin Cell Biol 1995; 7: 728-735.
8. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-1862.
9. David SG. The molecular perspective: matrix metalloproteinase 2. Stem Cells 2000; 18: 73-75.
10. Macaulay VM, O'Byrne KJ, Stunders MP, Braybrooke JP, Long L, Steson F et al. Phase E study intrapleural Batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-520.
11. Steward WP. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 1999; 43(Suppl): 50-60.
12. Dove A. MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med 2002; 8: 95.
13. Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003; 63: 600-607.
14. Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff C. Immunotherapy for melanoma. Cancer Control 2002; 9: 22-30.
15. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
16. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y et al. Immunogene therapy of tumors with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 11545-11550.
17. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
18. Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Ig leader sequence. Cancer Gene Ther 2001; 8: 9-16.
19. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. JBC 2003; 278: 21831-21836.
20. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999; 17: 343-348.
21. Jicha DL, Mulé JJ, Rosenberg SA. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174: 1511-1515.
22. Fields RC, Shimizu K, Mulé JJ.Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487.
23. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96: 1553-1558.
24. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H.Analysis of regulatory CD8T cells in Qa-1-deficient mice. Nat Immunol 2004; 5: 516-523.
25. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138: 3688-3694.
26. Pardoll DM. Inducing autoimmune diseases to treat cancer. Proc Natl Acad Sci USA 1999; 96: 5340-5342.
27. Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4T cells through an effect on quality of CTL. J Immunol 1999; 163: 184-193.
28. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN et al. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235-246.
29. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix. Metalloproteinases in response to angiogenic factors and Migration. J Invest Dermatol 1995; 105: 170-176.
30. Tara LH, Sandra JD, Joseph AM. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Bio Chem 1998; 273: 3604-3610.
31. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000; 97: 3884-3889.
32. Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.